Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01996839 · ClinicalTrials.gov registry record · Phase 3
Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 514
- Enrollment target
NCT01996839 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 514 participants.
The verdict
NCT01996839, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 514 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate ophthalmic gel
Interventions
- DRUG Loteprednol Etabonate Gel (BID)
- DRUG Loteprednol Etabonate Gel (TID)
- DRUG Vehicle (BID)
- DRUG Vehicle (TID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 514 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01996839
The ClinicalTrials.gov registry entry for NCT01996839 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 514 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Loteprednol Etabonate Gel (BID) is the first listed.
NCT01996839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01996839 about?
NCT01996839 is a clinical study titled "Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery". The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate ophthalmic gel
What is the current status of trial NCT01996839?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 514 participants. The study started on 2013-12. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01996839?
The interventions under investigation include: Loteprednol Etabonate Gel (BID) (DRUG), Loteprednol Etabonate Gel (TID) (DRUG), Vehicle (BID) (DRUG), Vehicle (TID) (DRUG).
Who is sponsoring clinical trial NCT01996839?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.